Table 1.
Included trials | Country | Total participants (T/C)* | Baseline thyroid function | Baseline vitamin D status† | Baseline 25(OH)D levels (T vs C) |
---|---|---|---|---|---|
Huang, 2013[51] | China | 32 (16/16) | Hypothyroidism | Insufficiency | 15.86 ± 3.56 vs 16.50 ± 2.81 ng/mL |
Han et al, 2015[50] | China | 62 (32/30) | Hypothyroidism | Not restricted | 17.91 ± 6.59 vs 18.22 ± 5.19 ng/mL |
Zhao et al, 2016[48] | China | 36 (18/18) | Hypothyroidism | Insufficiency | 16 ± 4 vs 16 ± 3 µg/L |
Parichehr Vahabi Anaraki et al, 2017[36] | Iran | 65 (33/32) | Hypothyroidism | Deficiency | 12.76 ± 0.74 vs 13.28 ± 0.86 ng/mL |
Zhou et al, 2018[49] | China | 122 (61/61) | Euthyroidism or Subclinical Hypothyroidism | Deficiency | 29.50 ± 19.65 vs NR‡ nmol/L |
Zuo et al, 2018[45] | China | 70 (35/35) | Euthyroidism | Deficiency | 10.61 ± 1.30 vs 13.58 ± 1.18 nmol/L |
Fu et al, 2019[34] | China | 70 (36/34) | Euthyroidism or Subclinical Hypothyroidism | Insufficiency | 15.08 ± 3.23 vs 13.99 ± 2.32 µg/L |
Reza Chahardoli et al, 2019[31] | Iran | 42 (21/21) | Hypothyroidism | Not restricted | 25.38 ± 11.02 vs 19.80 ± 8.81 ng/mL |
Jia, 2020[47] | China | 102 (51/51) | Hypothyroidism | Not restricted | 17.89 ± 6.38 vs 19.10 ± 6.51 ng/mL |
Xiao et al, 2020[44] | China | 80 (40/40) | Euthyroidism | Deficiency | 14.60 ± 5.08 vs 15.29 ± 6.88 ng/mL |
Zhang, 2020[46] | China | 90 (45/45) | Hypothyroidism | Deficiency | 17.16 ± 6.45 vs 18.24 ± 4.36 ng/mL |
Zhao, 2022[33] | China | 98 (49/49) | Euthyroidism or Subclinical Hypothyroidism | Insufficiency or Deficiency | 15.64 ± 5.54 vs 16.98 ± 5.43 ng/mL |
T: Treatment Group, C: Control Group.
Vitamin D Status: > 30 ng/mL (75 nmol/L) for sufficiency, 20–30 ng/mL (50–75 nmol/L) for insufficiency, < 20 ng/mL (50 nmol/L) for deficiency.
Not reported.